NEW YORK (GenomeWeb) – New data from a clinical study funded by the breast cancer charity Side-Out Foundation indicates the ability of multi-omic analyses to improve the effectiveness of therapy in patients with metastatic disease.

According to Emanuel Petricoin, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University and one of the leaders of the study, initial results from the second Side-Out study suggest that using molecular data to guide patient treatment extends progression-free survival in metastatic breast cancer patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.